
jul pm et
summari compani make market comprehens line product servic treat
price-to-earnings oper ep
risk assess reflect compani highli
competit industri character technolog
innov new market entrant rang
start-up establish medic product develop
compani must consist enhanc product
develop new one maintain competit stand
howev demand product immun econom
cycl tend exhibit stabl long-term unit price
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
expect sale grow
billion follow rise
see oper margin
expect continu organ growth
rang transcathet
heart valv therapi thvt busi
revenu increas
competit transcathet aortic valv
replac tavr market includ
corevalv
acur neo think ew lost
market share competitor lower price
altern recent quarter europ yet
launch ultra centera
expect ew regain share
maintain lead market share posit
market minimally-invas heart
across cardiovascular product intens
longer-liv age world popul aim
address heart diseas think thvt
market particip benefit
ew sizeabl net cash posit june
provid compani greater
financi flexibl peer
see ep grow
ep
recent upgrad opinion strong
buy buy share ew think
share trade
ep estim attract
valu although ew sale growth
moder recent quarter
optimist upcom product launch
centera valv tavr use
delay sapien ultra tavr ew leader
grow tavr space continu
expenditur favor
revenu vs
commit could lead breakthrough
develop technolog
minimally-invas mitral tricuspid valv
replac although technolog
difficult due anatom complex
believ ew could one first
compani market commerci viabl
risk recommend target
includ market share loss key product
categori difficulti commerci
product pipelin
target price reflect
multipl ep
estim peer faster
growth within ew five-year rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp ew develop manufactur market product
technolog design treat advanc stage cardiovascular diseas ew categor
product technolog three main area transcathet heart valv therapi thvt surgic heart
valv therapi shvt critic
ew leader transcathet heart valv replac technolog design nonsurg
replac heart edward sapien famili valv transcathet aortic heart valv
use treat patient heart valv diseas tradit open-heart surgeri sub-optimal ew
began offer transcathet heart valv patient commerci europ unit
state japan sale ew transcathet heart valv repres
net sale respect
shvt segment core product line carpentier-edward perimount pericardi valv platform
includ valv aortic mitral surgic valv replac ew leader shvt
includ product annuloplasti ring beating-heart mitral repair system ew acquir
harpoon medic inc decemb sale ew surgic tissu heart valv product
repres net sale respect
critic segment make hemodynam monitor system ew world leader
measur patient heart function fluid statu surgic intens care set hemodynam
monitor enabl clinician balanc suppli demand oxygen critic ill patient
play import role enhanc surgic recoveri enabl appropri tissu organ perfus
ultim enabl improv patient outcom surviv sale ew core
hemodynam product repres net sale
competit landscap cardiovascular diseas number one caus death world
top diseas term health care spend nearli everi countri cardiovascular diseas progress
tend worsen time often affect structur individu heart result
compani aim treat cardiovascular diseas highli profit face sever competit
cardiovascular segment medic technolog industri dynam subject signific
chang due cost-of-car consider regulatori reform industri custom consolid
thvt ew primari competitor includ plc boston scientif corpor abbott
laboratori shvt ew primari competitor includ plc
plc critic ew compet primarili varieti compani specif product line includ
inc pulsion medic system se lidco group plc
key maintain grow market share medic devic industri upkeep product
research develop program edward invest sizeabl portion sale effort
 spend million sale compar million
million expect compani continu invest heavili
ew make signific invest improv streamlin establish
transcathet aortic heart valv replac procedur addit ew make signific
invest develop transcathet heart valv technolog design treat mitral
tricuspid valv diseas structur heart condit valvular diseas difficult
treat aortic valv diseas therefor ew could stand benefit significantli pioneer one
first market therapi
financi trend revenu grew billion billion five-year
cumul annual growth rate compound-annual-growth-rate year end decemb adjust ep
compound-annual-growth-rate vs ew typic maintain net cash posit
gener posit free cash flow defin cash flow oper less capit expenditur free
cash flow million vs million compani capit structur posit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
ew slightli overvalu
neutral sinc juli technic indic ew
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
stop medicaid expans senat
fail multipl time gather
suffici number vote pass variou
repeal replac bill howev republican
success elimin individu
mandat passag tcja
decemb see develop
neg health care equip
compani fewer insur patient
futur like lead fewer procedur
expect hospit largest
consum medic equip
advers impact could pressur
sale medic equip compani
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index year
date june health
increas composit index
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
addit sub-industri mani product
area histor
use non-elect procedur
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
expans acquisit speed
new product come market
increas recent year
success effort food drug
administr fda reduc approv
time medic devic time
see price pressur incess head wind
medic equip compani although
hospit saw boost cash tcja
tax cut job act think
hospit cautiou capit
budget amid on-going shift value-bas
care loom roll-off
medic devic tax sought rais
total billion year took
effect mani compani implement
cost optim measur respons
medic devic excis tax suspend
sinc begin
suspend till end compani
health care equip sub-industri stand
benefit medic devic tax repeal
develop
question opinion
recent republican administr
 difficulti attempt
repeal afford act
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
lifesci corpor ew rais target
above-p next ep estim faster
growth sale includ germani stock sale rose
transcathet heart valv therapi w/o germani german client
stock due potenti suppli interrupt litig
ep vs estim rais ep
estim ew narrow sale guidanc
rais ep
et capit iq lift opinion share edward
lifesci buy hold ew share sharpli
see buy opportun expect ew maintain lead market share
amid increas competit moder sale growth keep
target peer ep estim
set ep estim sale rose transcathet
heart valv sale sale franc remain limit ew
negoti french polici limit procedur ep vs
ahead estim ew maintain sale guidanc
ep /jeffrey loo cfa
analyst research note compani news
et cfra upgrad opinion share edward lifesci
strong buy buy ew rais target
above-p ep estim
multipl higher end ew five-year rang
ep vs higher estim rais
ep ep
sale increas organ million driven growth
global transcathet heart valv therapi thvt busi
organ thvt revenu growth lower expect declin
market share outsid particularli europ competitor
price aggress think market overreact temporari
slowdown growth long-run think make sens ew maintain
premium price given technolog superior ew
life-sav thvt continu look forward launch sapien
ultra centera valv later year /kevin huang cfa
et cfra maintain buy opinion share edward
lifesci corpor ew maintain target
above-p next ep estim
multipl near middl ew five-year rang ep
vs higher estim rais ep
sale increas million
transcathet heart valv therapi thvt total sale
due difficult comparison prior-year period result
stock germani surgic heart valv therapi shvt
declin shvt primarili relat convers consign
inventori model surgic valv us result increas
sale reserv european sale focal point fell howev sale
would grown adjust germani stock foreign exchang
effect despit difficult quarter sale continu expect robust
adopt thvt global /kevin huang
et cfra reiter buy opinion share edward
lifesci corpor ew rais target
above-p ep estim
high-end five-year rang ep vs
ahead view set sale rose
transcathet heart valv therapi double-digit growth
region europ sale aid recoveri franc limit
number procedur last year see robust adopt transcathet
aortic valv replac tavr aid strong intern sale
tavr center /jeffrey loo cfa
et cfra keep buy opinion share edward lifesci
corpor ew lower target
forward ep estim within ew rang
ep vs estim lower
ep estim sale rose forecast
slowdown transcathet aortic valv replac tavr procedur
earlier year sizeabl slowdown believ
ew fundament remain intact still see robust growth tavr procedur
et cfra keep buy opinion share edward lifesci
ew rais target peer
next ep estim faster growth ep
vs ahead estim rais ep
estim sale rose
transcathet heart valv therapi sale rose robust therapi adopt
across geographi sale believ ew continu
expand market share expect new product includ ultra
centera launch europ later year help drive sale growth
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim ew earn
usd quarter fiscal year ew
announc earn per share usd repres
total revenu estim fiscal year
analyst estim ew earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
